Clinical Trials Sponsored by Stella Pharma Corporation

Total 1697 results

Ophthotech Corporation

Completed

A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration

Age-Related Macular Degeneration

United States
Ophthotech Corporation

Completed

A Study to Establish the Safety and Tolerability of Zimura® (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)

Idiopathic Polypoidal Choroidal Vasculopathy

United States
Ophthotech Corporation

Completed

ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)

Wet Age-related Macular Degeneration

United States, Hungary, Latvia
Ophthotech Corporation

Terminated

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

Age-Related Macular Degeneration

Israel, United States, Germany, Denmark, France, Turkey, Hungary, Colombia, Australia, Argentina, Spain
Ophthotech Corporation

Completed

A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration

Age-related Macular Degeneration

United States
Ophthotech Corporation

Completed

ARC1905 (ANTI-C5 APTAMER) Given Either In Combination Therapy With Lucentis® 0.5 mg/Eye In Subjects With Neovascular Age-Related Macular Degeneration

Age-Related Macular Degeneration

United States
Ophthotech Corporation

Withdrawn

ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)

Idiopathic Polypoidal Choroidal Vasculopathy

United States
Ophthotech Corporation

Completed

A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration

Age-Related Macular Degeneration

United States
Ophthotech Corporation

Terminated

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy

Age-Related Macular Degeneration

France, Israel, Italy, United States, Spain, Portugal, Germany, Austria, Canada, Czechia, Estonia, Latvia, Poland, Slovakia, Australia, Hungary, Croatia, Argentina, Finland, Brazil, Colombia, Norway
Ophthotech Corporation

Terminated

A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)

Age-Related Macular Degeneration

United States
Ophthotech Corporation

Completed

A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration

Age-related Macular Degeneration
Ophthotech Corporation

Terminated

Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD

Age-related Macular Degeneration

United States
Ophthotech Corporation

Terminated

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

Age-Related Macular Degeneration

Italy, Canada, Switzerland, United States, United Kingdom, Austria, Belgium, Brazil, Czechia, Estonia, Latvia, Poland, Slovakia
Cancer Intelligence Care Systems, Inc.
Stella Pharma Corporation

Completed

Boron Neutron Capture Therapy Using CICS-1 and SPM-011 for Malignant Melanoma and Angiosarcoma

Angiosarcoma | Malignant Melanoma

Japan
Stella Pharma Corporation
Cancer Intelligence Care Systems, Inc.

Recruiting

A Phase II Study by Using CICS-1 and SPM-011 Commissioned by CICS and STELLA PHARMA

Unresectable Angiosarcoma

Japan
Astellas Pharma S.A.S.

Completed

A Study of Renal Transplant Patients Converted From the Twice Per Day Form of Tacrolimus (Prograf®) to the Once Per Day Form (Advagraf®) (OPALE)

Renal Transplantation

France
Astellas Pharma S.A.S.

Completed

Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients (DAFNE)

Clostridium Difficile Infection

France
Astellas Pharma S.A.S.

Completed

A Multicenter Study in Liver Transplant Patients Converted From Prograf® to Advagraf® During the First Post-transplantation Year (COBALT)

Liver Transplantation

France
Astellas Pharma S.A.S.

Completed

Use of Micafungin (Mycamine®) as Antifungal Prophylaxis in Haematology and Onco-haematology (OLYMPE)

Antifungal Prophylaxis | Haemopathy

France
Astellas Pharma s.r.o.

Completed

A Study of Efficacy and Safety of Qutenza in Patients With Post-operative Peripheral Neuropathic Pain

Post-operative Peripheral Neuropathic Pain

Czech Republic
Dr Cipto Mangunkusumo General Hospital
Astellas Pharma Indonesia Inc.; Pharos Life Corporation

Unknown

The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Urinary Tract Infection in Females

Urinary Tract Infection

Indonesia
Astellas Pharma Inc
Astellas Pharma US, Inc.; Advanz Pharma

Completed

Response to RSD1235 Compared to Placebo in Subjects With Atrial Arrhythmia After Heart Surgery

Atrial Fibrillation | Atrial Flutter

Poland, United States, Canada, Argentina, Denmark, India
Astellas Pharma Korea, Inc.

Recruiting

A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation

Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

Korea, Republic of
Astellas Pharma China, Inc.

Completed

A Study to Evaluate the Safety and Efficacy of a Modigraf® Based Immunosuppression Regimen in De Novo Pediatric Allograft Liver and Kidney Transplantation Recipients

Liver Transplantation | Kidney Transplantation

China
Astellas Pharma China, Inc.

Completed

A Study of Modigraf® (Tacrolimus Granules) to Evaluate the Pharmacokinetics and Long-term Safety and Efficacy in De Novo Pediatric Allograft Liver and Kidney Transplantation Recipients

Liver Transplantation | Kidney Transplantation

China
Astellas Pharma China, Inc.

Completed

Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients

Kidney Transplant

China
Astellas Pharma China, Inc.

Completed

A Study to Assess the Safety and Tolerability of Fezolinetant in Women Seeking Treatment for Relief of Vasomotor Symptoms (VMS) Associated With Menopause (Moonlight 3)

Hot Flashes

China
Astellas Pharma China, Inc.

Completed

A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women in Asia Going Through Menopause (Moonlight 1)

Hot Flashes

Korea, Republic of, China, Taiwan
Astellas Pharma Europe Ltd.

Completed

A Study to Evaluate the ePidemiology of anEmia Associated With chroNic Kidney Disease in Patients in Primary Care Using The Stockholm CREAtinine Measurement (SCREAM) Register

Chronic Kidney Disease

Sweden
Astellas Pharma Korea, Inc.

Completed

Post Marketing Study to Evaluate the Efficacy and Safety of Solifenacin in Patients With OAB (Overactive Bladder) After TURP (Trans-urethral Resection of Prostate) or PVP (Photoselective Vaporization of Prostate) (POST-TURP)

Overactive Bladder | Benign Prostate Hyperplasia | Transurethral Resection of Prostate | Photoselective Vaporization Prostatectomy

Korea, Republic of
Astellas Pharma Korea, Inc.

Completed

A Study to Assess the Efficacy and Safety of Advagraf® Switching From Cyclosporine Between the Group That Was Treated With a 50% Reduced Corticosteroid and the Group With Maintained Corticosteroid for Stable Kidney Transplant Recipients (COSMOS)

Kidney Transplant

Korea, Republic of
Astellas Pharma Europe B.V.

Completed

A Study of ASP8302 in Participants With Underactive Bladder

Underactive Bladder

Japan, Poland, Germany, Netherlands, Slovakia, United Kingdom
Astellas Pharma Europe Ltd.

Completed

A Study to Compare How the Body Absorbs and Processes Two Different Formulations of the Anti-rejection Medication Tacrolimus (Advagraf® or Prograf®) in Children Receiving an Organ Transplant, and How Safe and Effective They Are Over a Longer Period of Time

Liver Transplantation | Kidney Transplantation | Heart Transplantation

Czechia, France, Italy, Poland, United Kingdom
Astellas Pharma China, Inc.

Completed

A Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus Nephritis

Lupus Nephritis

China
Astellas Pharma China, Inc.

Completed

A Study to Evaluate the Pharmacokinetics and Safety of ASP015K in Healthy Chinese Subjects

Healthy Volunteers

China
Astellas Pharma China, Inc.

Completed

A Study to Investigate the Effect of Food With Mirabegron in Healthy Chinese Participants

Pharmacokinetics of Mirabegron | Food Effect | Healthy Chinese Subjects

China
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder (Symphony)

Urologic Diseases | Urinary Bladder, Overactive | Urinary Bladder Diseases | Urological Manifestations | Signs and Symptoms

Belarus, Belgium, Czechia, Denmark, Finland, France, Germany, Hungary, Italy, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slovakia, Spain, Sweden, Ukraine, United Kingdom
Astellas Pharma a/s

Completed

A Non-interventional, Epidemiological, Registry-based Evaluation of Anaemia in Swedish Patients With Chronic Kidney Disease (ASK)

Chronic Kidney Disease Associated Anemia

Sweden
Astellas Pharma Europe Ltd.

Terminated

A Paediatric, Open, Follow up Study With Modigraf Examining Safety and Efficacy in de Novo Allograft Recipients (PROGRESSION)

Liver Transplantation | Kidney Transplantation | Heart Transplantation

Belgium, France, Germany, Poland, Spain, United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity

Neurogenic Detrusor Overactivity

United States, Belgium, Brazil, Denmark, Hungary, Korea, Republic of, Mexico, Philippines, Poland, Turkey
Astellas Pharma Europe Ltd.

Completed

Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant

Liver Transplantation | Kidney Transplantation | Heart Transplantation

Spain, Australia, France, Germany, Canada, Italy, United Kingdom, Belgium, South Africa, Switzerland, Sweden, United States, Austria, Brazil, Czechia, Denmark, Finland, Hungary, Ireland, Mexico, Netherlands, New Zealand, Poland
Astellas Pharma China, Inc.

Terminated

Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp

Candidiasis | Aspergillosis

China
Astellas Pharma Europe B.V.

Completed

A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC) (AMARANTH)

Pain | Urologic Diseases | Cystitis, Interstitial | Urinary Bladder Disease

Belgium, Czechia, Denmark, Germany, Latvia, Lithuania, Netherlands, Poland, Portugal, Romania, Russian Federation, Spain
Astellas Pharma Europe Ltd.

Completed

A 5 Year Follow-up of Patients Who Were Previously Enrolled Into an Advagraf Trial Following a Liver or Kidney Transplant (ADDRESS)

Liver Transplant | Kidney Transplant

Italy, Spain, Belgium, Germany, Latvia, Canada, Korea, Republic of, Czechia, Austria, Finland, Belarus, Estonia, France, Hungary, Ireland, Netherlands, Poland, Portugal, Romania, Russian Federation, Slovakia, Sweden, Switzerland, United...
Astellas Pharma Europe B.V.

Completed

A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076 (LEOPARD)

Urinary Bladder, Overactive

Belgium, United States, Brazil, Canada, Denmark, Former Serbia and Montenegro, Korea, Republic of, Mexico, Norway, Philippines, Poland, South Africa, Sweden, Turkey, Ukraine, United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug (LION)

Urinary Bladder, Overactive

Belgium, United States, Brazil, Canada, Denmark, Former Serbia and Montenegro, Korea, Republic of, Mexico, Norway, Philippines, Poland, South Africa, Sweden, Turkey, Ukraine, United Kingdom
Astellas Pharma Europe Ltd.

Completed

A Study to Compare the Finger Prick Whole Blood MITRA Assay Method With the Established Venepuncture Whole Blood Method for Quantitative Determination of Tacrolimus Blood Concentrations in Transplant Patients (MITRA)

Liver Transplantation | Kidney Transplantation

France, United Kingdom
Astellas Pharma Europe Ltd.

Completed

A Study to Determine Pharmacokinetics of Children Receiving Modigraf (Tacrolimus Granules) Following Solid Organ Transplantation (OPTION)

Liver Transplantation | Kidney Transplantation | Heart Transplantation

Belgium, France, Germany, Poland, Spain, United Kingdom
Astellas Pharma Europe Ltd.

Completed

Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI) (PROFILE)

Inflammatory Bowel Disease (IBD) | Clostridium Difficile Infection (CDI)

Austria, France, Greece, Italy, Poland, Russian Federation, United Kingdom
Astellas Pharma Europe Ltd.

Completed

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin) (BESIDE)

Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Overactive

United States, Armenia, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Greece, Hungary, Ireland, Israel, Italy, Lebanon, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slov... and more

3

Subscribe